Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized study of continuing versus stopping cytotoxic chemotherapy after 6 weeks in non-progressive metastatic esophageal squamous cell carcinoma
2010-021439-16Phase 2Completed
- Sponsor
- Centre Oscar Lambret
- Start
- Aug 2010
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of fluorouracil, folinic acid, cisplatin, docetaxel and oxaliplatin in Esophageal Squamous Cell Carcinoma (ESCC) (2 arms), sponsored by Centre Oscar Lambret. Primary endpoint: Overall survival. Started Aug 2010; status: completed.
02
Drugs
fluorouracilfolinic acidcisplatindocetaxeloxaliplatin
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on 2010-021439-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021439-16.